Pregabalin
Product Images NDC 45865-106

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 45865-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Capsules 50 mg (#30) (Pdp 106)

Pregabalin Capsules 50 mg label from Medsource Pharmaceuticals. The label indicates the product is generic for Lyrica with a package count of 30 capsules. It notes the color as white/oblong and includes instructions to take the capsule(s) as directed by a physician. The label displays the NDC 45865-0106-30 and cautions that the drug transfer is restricted by law.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at 200 mg, 100 mg, and 25 mg three times a day against a placebo, with separate lines for each dosage and placebo indicating patient response rates across pain improvement percentages.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The chart compares Pregabalin 100 mg three times a day with placebo, illustrating higher patient improvement percentages for Pregabalin across the range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved relative to percent improvement in pain from baseline. It compares Pregabalin dosages of 75 mg, 150 mg, and 300 mg taken two times a day versus a placebo, illustrating higher improvement rates with increasing doses of Pregabalin.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

Line chart showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The graph compares efficacy between the two dosages and placebo over varying pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved on the y-axis and percent improvement in pain from baseline on the x-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating trends in patient pain improvement percentages over a range from 0 to 100 percent.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) in two clinical studies, Study E1 and Study E3. Study E1 bars show responder rates for placebo and increasing doses of a drug up to 600 mg/day. Study E3 bars show responder rates for placebo, 300 mg/day BID, and 600 mg/day TID. Statistically significant differences versus placebo are marked with an asterisk.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day. The graph compares four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, with data points showing significant p-values for different doses, indicating seizure reduction trends with increasing dose.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares Pregabalin at daily doses of 300 mg, 450 mg, and 800 mg, plus a placebo. Multiple lines show the effectiveness trends for each dose versus placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without lead time relapse (LTR) over a 180-day period for Pregabalin versus placebo groups. The y-axis shows estimated percentage from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group line consistently remains above the placebo group line throughout the study period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to Week 12, showing Pregabalin versus Placebo. The x-axis represents percent improvement from baseline to Week 12 BOCF, while the y-axis indicates the percent of subjects improved. Pregabalin shows a higher improvement rate across all percentages compared to placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to week 16, using BOCF analysis. Two lines represent Pregabalin and Placebo, showing higher percent improvement for Pregabalin across the range. The x-axis shows percent improvement, and the y-axis shows the percent of subjects improved.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula showing the calculation for creatinine clearance (CLcr). The formula is: CLcr = [(140 - age in years) × weight in kilograms] divided by (72 × serum creatinine in mg/dL), with a multiplier of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of the active ingredient Pregabalin, showing its molecular arrangement including an amino group and a carboxylic acid group attached to a branched hydrocarbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.